Endpoints 11 winner Stipple Bio is aiming to be part of the future generation of therapies used for deadly pancreatic cancer.
Clive Meanwell and John Maraganore's Corsera Health is developing a once-yearly siRNA shot to prevent heart disease in ...
SonoThera is using ultrasound and microbubbles to push full-length dystrophin into muscle, with a $125M Series B and a 2027 ...
Vivodyne, backed by about $80M, grows vascularized human tissues to screen drugs as the FDA and NIH push alternatives to animal testing.
Brian Armstrong, Blake Byers Headquarters South San Francisco, CA Total raised $682M Key investors Kleiner Perkins, Founders ...
Doudna-co-founded Azalea Therapeutics aims to enter the clinic next year with a CRISPR-based in vivo CAR-T therapy for blood ...
Weihao Xu built Kali Therapeutics with $18M, no lab and Chinese vendors — then sold its lead T cell engager to Sanofi for ...
Endpoints News announces the winners of the 2026 Endpoints 11 awards: The best and most exiting biotech startups of the year.
On Dec. 1, Travere Therapeutics will have a new CEO for the first time in almost eight years, as Eric Dube hands the baton to ...
Alnylam alumni-led City Therapeutics files for a Nasdaq IPO under CTY, with $172M in cash and a Phase 1 factor XI siRNA.
Endpoints 11 winner Medra and founder Michelle Lee raised a $52M Series A to put 100+ AI robots to work in a bid to build self-driving biology labs.
Legend CEO Ying Huang is raising a $250M Series A for K2 Therapeutics, a Singapore-based hub stacked with eight China assets.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results